RT Journal Article
SR Electronic
T1 Comorbidity alters the genetic relationship between anxiety disorders and major depression
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.11.19.24317523
DO 10.1101/2024.11.19.24317523
A1 Tesfaye, Markos
A1 Shadrin, Alexey
A1 Parker, Nadine
A1 Jaholkowski, Piotr
A1 Parekh, Pravesh
A1 Kutrolli, Gleda
A1 Birkenæs, Viktoria
A1 Bakken, Nora R.
A1 Ask, Helga
A1 Frei, Oleksandr
A1 Djurovic, Srdjan
A1 Dale, Anders M.
A1 Smeland, Olav B.
A1 O’Connell, Kevin S.
A1 Andreassen, Ole A.
YR 2024
UL http://medrxiv.org/content/early/2024/11/20/2024.11.19.24317523.abstract
AB Importance There is extensive comorbidity between anxiety disorders (ANX) and major depression (MD). Most studies on the genetics of ANX do not exclude comorbid cases of MD, and vice versa, therefore confounding genetic association analyses. Disorder-specific analysis of genomic data may reveal more precise biological pathways and causal relationships.Objective To investigate the genetic relationship between disorder-specific ANX and MD compared to samples with comorbidity, including their causal relationship.Design, Setting, and Participants Data from UK Biobank was used to perform genome-wide association studies (GWAS) of ANX-only and MD-only, and generate disorder-specific polygenic risk scores (PRS). The Norwegian Mother, Father, and Child Cohort (MoBa) was used to test the associations of PRS with diagnosis and symptoms. MD and ANX GWAS data including comorbidities (MD-co and ANX-co) were used as comparators. Genetic correlation was assessed using LDSC, and Mendelian randomization was employed to infer causal relationships.Main Outcomes and Measures GWAS of ICD-10 diagnoses of ANX, MD, or both. Genetic correlations between pairs of ANX and MD phenotypes. PRS associations with diagnoses of ANX, MD, and their comorbid states, and anxiety or depressive symptoms.Results The GWAS of ANX-only (9,980 cases and 179,442 controls) and MD-only (15,301 cases and 179,038 controls) showed a lower genetic correlation (0.53) than the one between ANX-co and MD-co (0.90). ANX-only showed a causal relationship with MD-only (PFDR=1.5e-02), but not vice versa, while comorbid cases showed a significant bidirectional causal relationship (PFDR=2.9e-12, PFDR =9.3e-06). The PRS-MD-only were differentially associated with MD-only compared to ANX-only cases (β= -0.08; 95%CI: -0.11, -0.03); however, this differential association was not observed for the PRS-MD-co. A similar pattern of differential association with anxiety and depressive symptoms was observed for PRS-ANX-only, but not for PRS-MD-co.Conclusions and Relevance The genetics and underlying biology of ANX and MD are more distinct when comorbid cases are excluded from analyses and reveals that ANX may be causal for MD. This confounding of genetic relationships as a result of comorbidity is likely to apply to other psychiatric disorders. Disorder-specific genetic studies may help uncover more relevant biological mechanisms and guide more targeted clinical interventions.Question Is the high genetic correlation between anxiety disorders (ANX) and major depression (MD) due to phenotypic overlap (comorbidity) and will disorder-specific (non-comorbid) analysis provide insight into their underlying causal factors?Findings Applying statistical genetics tools in two large population samples (UK Biobank, n=500,000; and MoBa, n= 130,000), we found a smaller genetic correlation between MD and ANX when comorbid cases were excluded. Additionally, after excluding comorbid cases, Mendelian randomization revealed that genetic liability to ANX is causally linked to MD but not vice versa.Meaning The genetic overlap between ANX and MD may be driven by phenotypic comorbidity, which inflates their genetic correlation. The results support that ANX has a causal link to MD, suggesting that early interventions for ANX may prevent subsequent development of MD. Further, investigating the genetic underpinnings of ANX and MD, while excluding their comorbid states, may help advance precision medicine and uncover novel biological mechanisms.Competing Interest StatementOle A. Andreassen is a consultant for Cortechs.ai and Precision Health and has received speaker's honoraria from Lundbeck, Janssen, Otsuka, and Sunovion. Srdjan Djurovic has received speaker's honoraria from Lundbeck. Dr. Anders M. Dale is the Founding Director, holds equity in CorTechs Labs, Inc. (DBA Cortechs.ai), and serves on its Board of Directors and the Scientific Advisory Board. He is an unpaid consultant for Oslo University Hospital. The terms of these arrangements have been reviewed and approved by the University of California, San Diego in accordance with its conflict of interest policies. Dr. Frei is a consultant to Precision Health. The other authors have no conflicts of interest to declare.Funding StatementThe authors received support support from the Research Council of Norway (324252, 324499, 300309, 273291, 223273, 248778, 273446, 326813, 334920, 271555/F21, 324620), NordForsk (grant 156298), the European Economic Area and Norway Grants (EEA-RO-NO-2018-0535, EEA-RO-NO-2018-0573), the South-East Norway Regional Health Authority (2022-087 and 2022-073), The University of Oslo, KG Jebsen Stiftelsen (SKGJ-MED-021), the European Unions Horizon 2020 research and innovation program (847776, 964874), and Marie Skłodowska-Curie grant (801133), and the US National Institutes of Health (R01MH123724-01, R01MH124839-02, U24DA041123, R01AG076838, U24DA055330, and OT2 HL161847). The Norwegian Mother, Father and Child Cohort Study is supported by the Norwegian Ministry of Health and Care Services and the Ministry of Education and Research. This research is part of the HARVEST collaboration, supported by the Research Council of Norway (grant 229624). The Norwegian Centre for Mental Disorders Research (NORMENT) provided genotype data, funded by the Research Council of Norway (grant 223273), South East Norway Health Authorities, and Stiftelsen Kristian Gerhard Jebsen. The Center for Diabetes Research, the University of Bergen, provided genotype data funded by the ERC AdG project SELECTionPREDISPOSED, Stiftelsen Kristian Gerhard Jebsen, the Trond Mohn Foundation, the Research Council of Norway, the Novo Nordisk Foundation, the University of Bergen, and the Western Norway Health Authorities. This work was performed on the TSD (Tjeneste for Sensitive Data) facilities, owned by the University of Oslo, operated and developed by the TSD service group at the University of Oslo, IT-Department (USIT). This research has been conducted using the UK Biobank Resource under Application Number 27412.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Regional Committee for Medical and Health Research Ethics approved the present study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.